Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978599 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of AVL-3288 in Schizophrenia Patients
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02978599 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 24 participants.
The verdict
NCT02978599, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients with schizophrenia.
Interventions
- DRUG Placebo
- DRUG AVL-3288
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02978599
The ClinicalTrials.gov registry entry for NCT02978599 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02978599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02978599 about?
NCT02978599 is a clinical study titled "Clinical Trial of AVL-3288 in Schizophrenia Patients". Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients with schizophrenia.
What is the current status of trial NCT02978599?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-11. Estimated completion is 2018-11-02.
What interventions are being tested in trial NCT02978599?
The interventions under investigation include: Placebo (DRUG), AVL-3288 (DRUG).
Who is sponsoring clinical trial NCT02978599?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.